PS
AXSM icon

Principal Securities’s Axsome Therapeutics AXSM Stock Holding History

Principal Securities’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-33
Closed -$4.01K – 1530
2025
Q3 		$4.01K Buy
33
+5
+18% +$563 ﹤0.01% 3026
2025
Q2 		$2.92K Buy
28
+20
+250% +$2.12K ﹤0.01% 3021
2025
Q1 		$677 Hold
8
– – ﹤0.01% 3295
2024
Q4 		$677 Hold
8
– – ﹤0.01% 3288
2024
Q3 		$719 Buy
8
+5
+167% +$436 ﹤0.01% 3210
2024
Q2 		$242 Hold
3
– – ﹤0.01% 3288
2024
Q1 		$239 Hold
3
– – ﹤0.01% 3224
2023
Q4 		$239 Buy
+3
New +$201 ﹤0.01% 3134

Other funds holding AXSM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Principal Securities's AXSM Position: Q4 2025 in Review

Principal Securities sold out of Axsome Therapeutics (AXSM) in Q4 2025, closing a stake of 33 shares — an estimated $4.01K sold.

Principal Securities first reported a position in AXSM in Q4 2023 and held it in 8 quarters. The position peaked at $4.01K in Q3 2025. 398 funds tracked by Wall St. Rank hold AXSM as of Q4 2025.

  • Principal Securities reported no remaining Axsome Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Principal Securities sold 33 Axsome Therapeutics shares in Q4 2025, an estimated $4.01K.
  • Principal Securities first reported a position in Axsome Therapeutics in Q4 2023 and held it in 8 quarters.
  • Principal Securities's Axsome Therapeutics position peaked at $4.01K in Q3 2025.
  • 398 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q4 2025.

Based on Principal Securities's 13F filing for Q4 2025, filed 12 Feb 2026.